XHKG
0570
Market cap782mUSD
Oct 09, Last price
1.27HKD
1D
4.10%
1Q
-11.19%
Jan 2017
-64.62%
Name
China Traditional Chinese Medicine Holdings Co Ltd
Chart & performance
P/E
—
P/S
0.37
EPS
—
Div yield, %
7.09%
Shrs. gr., 5y
—
Rev. gr., 5y
-0.08%
Revenues
14.74b
-10.69%
Net income
-342m
L
CFO
2.28b
-11.71%
Dividend
Jul 03, 20250.0865 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China Traditional Chinese Medicine Holdings Co. Limited functions as an investment holding company, primarily focusing on the research, development, and sale of traditional Chinese medicine and other pharmaceutical goods across the People's Republic of China. The company's product range includes medicinal granules, finished pharmaceutical preparations, pre-portioned decoction materials, and various healthcare products. Furthermore, its operations extend to the cultivation and management of Chinese medicinal herbs, the manufacturing of traditional Chinese medicines, and the trading of pharmaceutical products. It also delivers marketing, advertising, and consulting services related to TCM, and operates retail outlets for pharmaceuticals and decoction products. Property leasing services represent another facet of its business. The company distributes its products to healthcare facilities and retail pharmacies. Established in 1573 and headquartered in Wan Chai, Hong Kong, the firm was formerly known as China Traditional Chinese Medicine Co. Limited before adopting its current name in July 2016.
Key people
Xian Wu
Executive Chairman of the Board · since 2013
Xingkai Wang
Chief Financial Officer · since 2018
Yinglong Chen
Vice President · since 2018
Xueren Cheng
Vice President · since 2018
He Huang
Vice President · since 2018
Qingshan Lan
Vice President · since 2018
Qingsheng Zhang
Vice President · since 2013
Xiaochun Wang
President, Managing Director, Executive Director · since 2017
Wenming Yang
Vice President, Executive Director · since 2018
Joint Company Secretary · since 2017
Dongji Zhao
Vice President, Joint Company Secretary, Chief Legal Advisor · since 2019
Kaipin Kui
Non-Executive Director · since 2018
Kan Wang
Non-Executive Director · since 2018
Shanhua Yang
Non-Executive Director · since 2018
Binghua Yang
Non-Executive Director · since 2018
Weidong Li
Non-Executive Independent Director · since 2019
Independent Non-Executive Director · since 2013
Bajun Zhou
Non-Executive Independent Director · since 2013
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||